All HHS Contracts — September 11, 2026

The cost-plus-fixed-fee structure and full obligation of $146.7M provide predictable, low-risk revenue for Sanofi through 2016, with options potentially raising total value to $507.6M.

The $518M firm-fixed-price delivery order for the DCIPHER Ecosystem places significant cost-overrun risk on a small business, despite $413M already outlaid indicating strong performance to date.

With $50.5M already outlaid and a CPFF structure, Philips benefits from steady cash flow and low margin risk on a pandemic-era biodefense contract that runs through December 2026.

I3 Federal LLC, an SDVOSB, must manage fixed-price risk on a $518M CDC IT contract. Any cost overruns directly impact margins, and small business capacity constraints could hinder performance.

BARDA funding for pandemic preparedness may normalize post-COVID, potentially reducing follow-on contract opportunities for Sanofi/Protein Sciences and Philips North America beyond current obligations.

Two of three contracts (Sanofi/Protein Sciences and Philips) are from BARDA, creating agency-specific concentration risk for investors tracking HHS biodefense spending.

BARDA's continued investment in biodefense R&D, evidenced by the Sanofi/Protein Sciences ($146.7M) and Philips ($68.2M) contracts, signals stable demand for pandemic preparedness technologies. Follow-on contracts or option exercises could provide additional revenue.

CDC's $518M DCIPHER Ecosystem contract with I3 Federal underscores HHS IT modernization priorities. Similar large-scale IT contracts may be awarded to other vendors as agencies upgrade infrastructure.

Two BARDA contracts (Sanofi/Protein Sciences $146.7M and Philips $68.2M) demonstrate continued government investment in biological threat detection and medical countermeasures, even as pandemic-era urgency normalizes.

The $518M DCIPHER Ecosystem award to SDVOSB I3 Federal reflects CDC's push to modernize core IT infrastructure while leveraging set-aside programs. Fixed-price structure transfers cost risk to contractors.

{"entity" => "I3 Federal LLC", "reason" => "Holds a $518M fixed-price CDC IT contract with execution risk as an SDVOSB; contract runs through 2027.", "trigger" => "CDC DCIPHER Ecosystem renewal or re-compete announcement; any parent company disclosure or M&A activity"}

{"entity" => "Sanofi (SNY)", "reason" => "Subsidiary Protein Sciences Corp has a $146.7M BARDA contract with options up to $507.6M; post-2016 follow-on contracts are unknown.", "trigger" => "BARDA budget requests; any new BARDA awards to Sanofi/Protein Sciences; option exercise announcements"}

{"entity" => "Philips North America LLC (PHG)", "reason" => "Holds a $68.2M BARDA contract through 2026; 74% already funded, but follow-on opportunities depend on BARDA budget.", "trigger" => "BARDA budget requests; contract modifications or extensions beyond 2026"}